Veritas Genetics

Veritas Genetics is a personal genomics startup based in Danvers, Massachusetts.[1] It was co-founded in 2014 by George M. Church, Mirza Cifric, Preston Estep, and Jonathan Zhao.[2]

Veritas Genetics
TypePrivate
IndustryBiotechnology
Personal genomics
Founded2014
FoundersGeorge M. Church
Mirza Cifric
Preston Estep
Jonathan Zhao
Headquarters
Danvers, Massachusetts
,
United States
Key people
Mirza Cifric (CEO)
Preston Estep (Chief Scientific Officer)
ProductsmyGenome
Websitewww.veritasgenetics.com

In 2018, the company launched its flagship product, myGenome, with the stated goal of providing consumers with information about their genetic risk for disease and allergic reactions based on whole-genome sequencing results. The company's decision to sell the product for only $199 per order during an initial period attracted media attention as this promotional price was far below traditional prices for consumer-grade genome sequencing at the time.[1][3][4][5][6]

CNBC included the company on its Disruptor 50 list in 2018[1] and 2019.[7]

In December 2019, the company announced that it was ceasing U.S. operations and laying off most of its employees due to its inability to raise further funding.[8]

In January 2020, the company reversed course and announced that it had obtained further funding, would resume U.S. operations, and would rehire many of its employees.[9]

References
  1. "Veritas Genetics 2018 Disruptor 50". CNBC. 2018-05-22. Retrieved 2019-07-02.
  2. "Why Are We Here?". Veritas Genetics. Retrieved 2019-07-01.
  3. Khan, Razib; Mittelman, David (December 2018). "Consumer genomics will change your life, whether you get tested or not". Genome Biology. 19 (1): 120. doi:10.1186/s13059-018-1506-1. ISSN 1474-760X. PMC 6100720. PMID 30124172.
  4. Regalado, Antonio (2016-03-04). "One DNA Test to Rule Them All". MIT Technology Review. Retrieved 2019-07-02.
  5. Molteni, Megan (2018-11-19). "Now You Can Sequence Your Whole Genome for Just $200". Wired. ISSN 1059-1028. Retrieved 2019-07-02.
  6. Andrews, Joe (2019-07-01). "23andMe competitor Veritas Genetics slashes price of whole genome sequencing 40% to $600". CNBC. Retrieved 2019-07-02.
  7. "Veritas 2019 Disruptor 50". CNBC. 2019-05-15. Retrieved 2019-07-02.
  8. Farr, Christina (2019-12-05). "Veritas Genetics, the start-up that can sequence a human genome for less than $600, ceases US operations and is in talks with potential buyers". CNBC. Retrieved 2020-11-18.
  9. "Veritas Genetics Restarts US Business With Near-Term Financing". GenomeWeb. Retrieved 2020-11-18.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.